Cargando…

The therapeutic potential of targeting minimal residual disease in melanoma

BACKGROUND: Cutaneous melanoma is a lethal form of skin cancer with morbidity and mortality rates highest amongst European, North American and Australasian populations. The developments of targeted therapies (TTs) directed at the oncogene BRAF and its downstream mediator MEK, and immune checkpoint i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Riyaben P, Somasundram, Pretashini M, Smith, Lorey K., Sheppard, Karen E., McArthur, Grant A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040726/ https://www.ncbi.nlm.nih.gov/pubmed/36967556 http://dx.doi.org/10.1002/ctm2.1197

Ejemplares similares

Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
por: Dixon-Douglas, Julia R., et al.
Publicado: (2022)

Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies
por: Alkaraki, Arwa, et al.
Publicado: (2021)

Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?
por: Smith, Lorey K., et al.
Publicado: (2020)

Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma
por: Lau, Peter Kar Han, et al.
Publicado: (2021)

CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAF(V600) Melanoma via a p53 Dependent Pathway
por: Santiappillai, Nancy T., et al.
Publicado: (2021)

Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
por: Lelliott, Emily J., et al.
Publicado: (2022)

Genome-wide RNAi screen for genes regulating glycolytic response to vemurafenib in BRAF(V600) melanoma cells
por: Smith, Lorey K., et al.
Publicado: (2020)

Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF(V600) melanoma
por: Smith, Lorey K., et al.
Publicado: (2022)

Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
por: Lelliott, Emily J., et al.
Publicado: (2021)

Targeting oncogenes in advanced melanoma
por: McArthur, GA
Publicado: (2012)

Molecular Therapeutic Advances in Personalized Therapy of Melanoma and Non-Small Cell Lung Cancer
por: Kelleher, Fergal C., et al.
Publicado: (2012)

Novel combination therapies for BRAF-mutant melanoma
por: McArthur, Grant A
Publicado: (2015)

PRMT5: An Emerging Target for Pancreatic Adenocarcinoma
por: Lee, Michael K. C., et al.
Publicado: (2021)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
por: McArthur, Grant A.
Publicado: (2015)

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches
por: Cescon, David W., et al.
Publicado: (2022)

On the way to specifically targeting minimal residual disease?
por: Gebauer, Gerhard
Publicado: (2008)

Targeting melanoma residual disease by USP7
por: Vishnoi, Monika, et al.
Publicado: (2018)

A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy
por: Lelliott, Emily J., et al.
Publicado: (2019)

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
por: Lau, Peter Kar Han, et al.
Publicado: (2021)

Phenotype Switching in Melanoma: Implications for Progression and Therapy
por: Li, Frederic Zhentao, et al.
Publicado: (2015)

Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma
por: Wong, Stephen Q., et al.
Publicado: (2014)

Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours
por: Wong, Stephen Q., et al.
Publicado: (2013)

TRPM2 Channels: A Potential Therapeutic Target in Melanoma?
por: Foster, Hattie M., et al.
Publicado: (2023)

Cellular dormancy in minimal residual disease following targeted therapy
por: Ruth, Jason R., et al.
Publicado: (2021)

Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146
por: Rapanotti, Maria Cristina, et al.
Publicado: (2017)

Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome
por: Tan, Lih Yin, et al.
Publicado: (2016)

Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

Evolving treatments and future therapeutic targets in desmoplastic melanoma
por: Hadfield, Matthew J., et al.
Publicado: (2021)

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
por: Noori, Somayya, et al.
Publicado: (2023)

Targeted therapeutics in melanoma
por: Ali, Z, et al.
Publicado: (2012)

COX-2 as a potential biomarker and therapeutic target in melanoma
por: Tudor, Diana Valentina, et al.
Publicado: (2020)

Minimal residual disease in pediatric ALL
por: Pui, Ching-Hon, et al.
Publicado: (2017)

Minimal Residual Disease, Metastasis and Immunity
por: Badia-Ramentol, Jordi, et al.
Publicado: (2021)

Methods to detect minimal residual disease
por: Haferlach, Torsten
Publicado: (2018)

Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
por: AbuHammad, Shatha, et al.
Publicado: (2019)

Tumour mutation status and sites of metastasis in patients with cutaneous melanoma
por: Adler, Nikki R, et al.
Publicado: (2017)

Pathways and therapeutic targets in melanoma
por: Shtivelman, Emma, et al.
Publicado: (2014)

Novel Therapeutic Targets in Melanoma
por: Cerezo, Michaël, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n265okfiutk3buiid7fi7je95f